Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Publisher Name :
Date: 31-Jul-2013
No. of pages: 78
Inquire Before Buying

Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Shionogi & Co., Ltd. – Product Pipeline Review – 2013″ provides data on the Shionogi & Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Shionogi & Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Shionogi & Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Shionogi & Co., Ltd. – Brief Shionogi & Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Shionogi & Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Shionogi & Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Shionogi & Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Shionogi & Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Shionogi & Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas.

Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Shionogi & Co., Ltd. Snapshot 8
Shionogi & Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Shionogi & Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Shionogi & Co., Ltd. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Shionogi & Co., Ltd. - Pipeline Products Glance 17
Shionogi & Co., Ltd. - Late Stage Pipeline 17
Phase III Products/Combination Treatment Modalities 17
Shionogi & Co., Ltd. Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Shionogi & Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Shionogi & Co., Ltd. - Drug Profiles 22
(irbesartan + trichlormethiazide) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(lidocaine + prilocaine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
39-f 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Actair 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Benzimidazole Derivative 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Beta-Secretase Inhibitor 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Compound-18e 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
doripenem 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
duloxetine hydrochloride DR 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
guanfacine hydrochloride ER 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon gamma-1a 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese Cedar Pollen Tablet 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lisdexamfetamine dimesylate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lusutrombopag 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
naldemedine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ospemifene 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
oxycodone hydrochloride 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
P2X3 Receptor Antagonist 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Peptide Cocktail Vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prednisolone acetate 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
S-117957 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
S-120083 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
S-222611 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
S-234462 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
S-288310 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
S-488210 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
S-488410 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
S-555739 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
S-556971 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
S-646240 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
S-649266 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
S-707106 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
velneperit 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Shionogi & Co., Ltd. - Pipeline Analysis 55
Shionogi & Co., Ltd. - Pipeline Products by Therapeutic Class 55
Shionogi & Co., Ltd. - Pipeline Products By Target 59
Shionogi & Co., Ltd. - Pipeline Products by Route of Administration 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action 61
Shionogi & Co., Ltd. - Recent Pipeline Updates 63
Shionogi & Co., Ltd. - Dormant Projects 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products 70
Discontinued Pipeline Product Profiles 70
ADX-415 70
clonidine hydrochloride 70
doripenem 70
lusutrombopag 71
S-444823 71
S-5751 71
S-777469 71
S-8510 71
teceleukin 72
velneperit 72
Shionogi & Co., Ltd. - Company Statement 73
Shionogi & Co., Ltd. - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Shionogi & Co., Ltd. - Key Manufacturing Facilities 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Shionogi & Co., Ltd., Key Information 8
Shionogi & Co., Ltd., Key Facts 8
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 12
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Phase III, 2013 17
Shionogi & Co., Ltd. - Phase II, 2013 18
Shionogi & Co., Ltd. - Phase I, 2013 19
Shionogi & Co., Ltd. - Preclinical, 2013 20
Shionogi & Co., Ltd. - Discovery, 2013 21
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 56
Shionogi & Co., Ltd. - Pipeline By Target, 2013 59
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
Shionogi & Co., Ltd. - Recent Pipeline Updates, 2013 63
Shionogi & Co., Ltd. - Dormant Developmental Projects,2013 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products, 2013 70
Shionogi & Co., Ltd., Other Locations 74
Shionogi & Co., Ltd., Subsidiaries 75
Shionogi & Co., Ltd., Key Manufacturing Facilities 76

List of Figures
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 11
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 55
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Growth in the Indian Watch Industry
    Earlier, in India watches were seen as a luxury item. However, watches are now witnessing a fundamental change in perception, and are now gaining respect as an essential utility item. With the liberalization of the Indian market, coupled with the rising purchasing power of the young and consumerist Indians, watch industry in India seems to [...]
  • Global Retail Ready Packaging Market to Witness Steady Growth
    The market for retail ready packaging has witnessed impressive growth in recent years with boom in the retail industry. Retail ready packaging, also known as shelf-ready packaging is designed for the retail outlet, ready to be placed on shelf without any need for unpacking or repacking. In 2011, the global market for retail packaging was [...]
  • Venezuela Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Foreign currency controls and drug price cuts will continue to affect pharmaceutical companies' profitability, with the currency devaluation and high inflation exacerbating the situation. A close relationship and effective communication with the Venezuelan government are vital for the survival of domestic pharmaceutical companies. As the Venezuelan government tries to increase access to medicines, more co-ordination with drug producers to address these issues will become necessary. Hea......
  • Bahrain Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 101
    BMI View: This quarter has seen the beginning of a multi-phased plan by the National Health Regulatory Authority to significantly reduce medicine prices in the country, signalling a potential advancement towards the implementation of a unified Gulf Cooperation Council pricing system. Although less optimistic than before, our medium- and long-term outlooks for the Bahrain pharmaceutical market remain bullish. Medicines uptake will be supported by robust economic growth, in addition to the country......
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 65
    BMI View: Low health and pharmaceutical expenditures will continue to limit the attractiveness of the pharmaceutical market in Cambodia. Given such a profile, the country will present more commercial benefits to companies dealing with inexpensive generic drugs and over-the-counter products than innovative pharmaceuticals. Headline Expenditure Projections ? Pharmaceuticals: KHR828.7bn (US$210mn) in 2013 to KHR921.9bn (US$230mn) in 2014; +11.2% in local currency terms and +11.8% in US dollar terms......
  • Czech Republic Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 104
    BMI View: Overall, the Czech healthcare system is facing severe challenges as it struggles to contain budget deficits. At the same time, demand for the latest pharmaceuticals and access to healthcare services is expected to continue its steady growth trajectory, putting pressure on the state and insurers to raise premiums or redistribute funding. Following the release of pharmaceutical sales data by the SUKL, we have significantly revised down historical values for 2013 and forecasts from 2014 o......
  • Denmark Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 60
    BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities for private healthcare providers to expand as the government continues its restructuring and cost containment measures across the public healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: DKK20.20bn (US$3.58bn) in 2013 to D......
  • Iraq Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 75
    BMI View: The projected growth of Iraq's pharmaceutical market in 2014 and 2015 is linked to an oildriven economic expansion, which is dependent on the government's ability to represent and appease the country's factions. Given the government's expansionary fiscal policy, spending on education, health and public services will be elevated over the coming quarters. In particular, Baghdad will seek to modernise healthcare provision, in a view to improve support to its rule. Nevertheless, there are ......
  • Lithuania Pharmaceuticals and Healthcare Report Q2 2014
    Published: 16-Apr-2014        Price: US $1295 Onwards        Pages: 98
    BMI View: We expect the Lithuanian pharmaceutical market to post a five-year compound annual growth rate (CAGR) of 4.4%, rising to a value of LTL2.16bn (US$751mn) in 2018. While double-digit annual growth rates are firmly in the past, some opportunities continue to exist in light of epidemiological factors and an ageing population. The upcoming switch to the euro promises to boost purchasing power and stabilise the pharmaceutical market. However, the Lithuanian market will continue to represent ......
  • China Pharmaceutical Distribution Industry Report, 2013
    Published: 15-Apr-2014        Price: US $2400 Onwards        Pages: 110
    Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. As the leading players in China’s pharmaceutical distribution industry, Shanghai Pharma, Jointown and China National Accord Medicines achieved the revenue of RMB58.1 billion , RMB24.8 billion , RMB15.8 billion, respectively, in the first three quarters of 2013. In terms......
  • Carbohydrase Market by Applications (Food & Beverage, Animal Feed, Pharmaceuticals and Others), by Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, and Plants) and by Geography – Global Trends & Forecasts to 2019
    Published: 15-Apr-2014        Price: US $4650 Onwards        Pages: 233
    Enzymes, used as processing aids, are the key differentiation factors for industrial manufacturers and a great source of product innovation and differentiation. The market for carbohydrase is expected to experience a growth of 6.6% from 2013 to 2019. The estimation is a result of regular research and developments in the industry, with widening application of carbohydrases, which are mainly involved in the conversion of carbohydrates to simple sugars. Carbohydrase has major applications within......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs